Abstract:Background: Multiple myeloma (MM) is a plasma cell cancer for which immunotherapy holds the promise of durable control. To date, cancer vaccines mainly focused on tumor-associated antigens with survivin eliciting protective T-cell responses in both preclinical and clinical studies. Given the success of mRNA vaccines in medicine, we developed Galsomes, lipid nanoparticles containing mRNA and α-galactosyl ceramide to activate both CD8+ T cells and invariant natural killer (iNK) T cells, both potential anti-MM effectors. Materials and Methods: Mouse 5T33MM cells were studied by PCR and flow cytometry (FCM) for expression of survivin and CD1d, respectively. Intravenous (IV) prime-boost Galsome vaccination was performed with a 7-day interval in C57BL6/KalwRij mice that received an IV injection of 5x106 5T33MM cells 3 days earlier. As a control, mice were injected with saline. After 2 weeks, MM burden was studied by serum electrophoresis and FCM, incl. expression of CD1d and PD-L1 on MM cells. Activation of iNKT cells and survivin-specific T cells was studied by measuring IFN-γ secretion in ELISA and dextramer staining. Immunopeptidomics was used to identify new vaccine candidates for which Galsome vaccination is ongoing. Result: The 5T33MM cells showed expression of survivin and CD1d, making it a suitable model for Galsome vaccination. Two weeks following prime-boost vaccination, the serum M-protein was reduced, though not significantly. In contrast, MM cells were significantly reduced in bone marrow and spleen. Expression of CD1d and PD-L1 on MM cells was high but unchanged by Galsome vaccination. Activation of iNKT cells and survivin-specific T cells following prime vaccination was shown. However, following boost vaccination these cell populations reduced significantly compared to control. We repeated prime-boost vaccination in healthy mice, observing a similar outcome. This suggests that the negative effect of the boost Galsome vaccination was not related to immune dysfunctionality due to MM progression. So, we studied the impact of survivin mRNA in the vaccine, as survivin is also expressed in activated T cells, making them a potential target. We observed that iNKT cells and ovalbumin-specific T cells were more reduced when ovalbumin mRNA was paired with survivin mRNA in the Galsomes. To identify other vaccine candidates, we studied peptides eluted from MHC-I/peptide complexes on 5T33MM cells. We selected 4 vaccine candidates including the MM idiotype based on immunogenicity, pathway classification and abundance. mRNA and Galsomes were prepared, and the efficacy of these Galsomes in 5T33MM mice is currently under evaluation. Conclusion: These data show that Galsome vaccination has the potential to reduce MM cell levels. To reach higher efficacy, careful selection of the vaccine antigen is required. Moreover, combination with other immunotherapies might be needed to reach durable disease control. Citation Format: Arne Van der Vreken, Fabien Thery, Sofie Meulewaeter, Karin Vanderkerken, Elke De Bruyne, Kim De Veirman, Lorenzo Franceschini, Rein Verbeke, Francis Impens, Ine Lentacker, Karine Breckpot, Eline Menu. Identification of tumor peptides for therapeutic mRNA vaccination in a mouse multiple myeloma model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4110.

Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes

Nanomaterial‐Mediated Delivery of MLKL Plasmids Sensitizes Tumors to Immunotherapy and Reduces Metastases

mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends

Inactivation of necroptosis-promoting protein MLKL creates a therapeutic vulnerability in colorectal cancer cells

Nonlysosomal Route of Mrna Delivery and Combining with Epigenetic Regulation Optimized Antitumor Immunoprophylactic Efficacy.

MLKL in cancer: more than a necroptosis regulator

Intratumoral injection of mRNA encoding survivin in combination with STAT3 inhibitor stattic enhances antitumor effects

Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model

A novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models

Abstract B059: Signaling Requirements for Enhanced CD8+ T Cell Responses in mRNA Cancer Vaccine Immunotherapy

Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity

Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity

Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models

Abstract 4110: Identification of tumor peptides for therapeutic mRNA vaccination in a mouse multiple myeloma model

Tumor Regression Following Engineered Polyomavirus-Specific T Cell Therapy in Immune Checkpoint Inhibitor-Refractory Merkel Cell Carcinoma

Noninvasive Transdermal Administration of mRNA Vaccines Encoding Multivalent Neoantigens Effectively Inhibits Melanoma Growth

Immunotherapeutic treatment of lung cancer and bone metastasis with a mPLA/mRNA tumor vaccine

Abstract 3232: Combination therapy with onco-selective mRNA LNPs targets the complex immunosuppressive tumor microenvironment and is well tolerated at efficacious doses

Exth-15. An Egfrviii Rna-Lnp Vaccine Prototype Achieves Tumour Clearance In A Gbm Mouse Model

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors

Abstract 5002: Next-generation mRNA-LNP vaccine prototype achieves tumor clearance in a GBM mouse model